Breakthrough by Polish scientists saving heart disease patients
December 3, 2024
Medinice expects that next year two leading innovative medical projects will be ready for expansion. The company’s positive scenario includes the approval of PacePress and CoolCryo for the European market and CoolCryo for the US market, revealed Sanjeev Choudhary, co-founder, largest shareholder, and CEO of Medinice, to Strefa Biznesu.
Heart disease affects over 59 million people worldwide, and by 2040 this number will reach around 120 million. According to WHO, 29% of deaths are caused by heart diseases and strokes, which together are the fastest-growing threat to our civilization. Therefore, it is no longer surprising that the number of cardiac surgeries performed in the last 20 years has increased by over 50%.
In response to the growing demands of the dynamic healthcare market, the publicly traded company Medinice is developing advanced medical technologies (medtech sector). The projects underway have the potential not only to improve treatment effectiveness but also to reduce hospitalization time and therapy costs.
We Care About Your Privacy
Medinice S.A. uses cookies to improve and customize users experience on our website. By selecting 'Accept', you consent to the use of all cookies that gather and use information about your interactions with our site to provide personalized content and enhance your digital experience. Please read our Privacy Policy for more information.